Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Discontinuation as a result of evaluating circumstances, including the development status of SGLT2 inhibitors by competitors
Subscribe to our email newsletter
Kissei Pharmaceutical announced that GlaxoSmithKline has discontinued the development of the novel agent for diabetes, remogliflozin (KGT-1681). It was as a result of evaluating circumstances including the development status of SGLT2 inhibitors by competitors.
Kissei has discovered the SGLT2 inhibitor, remogliflozin and the SGLT1 inhibitor, KGA-3235 for diabetes, and licensed the development and marketing right of the agents in the US and Europe to GlaxoSmithKline.
Remogliflozin is in the stage of phase-II clinical studies, whereas KGA-3235 is in the stage of phase-I clinical study.
With regard to the development of SGLT inhibitors, GlaxoSmithKline has decided to continue to develop KGA-3235.